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Simple Summary: Despite the adoption of aggressive, multimodal treatment schedules, the cure
rate of high-grade osteosarcoma (HGOS) has not significantly improved in the last 30 years. The
most relevant problem preventing improvement in HGOS prognosis is drug resistance. Therefore,
validated novel biomarkers that help to identify those patients who could benefit from innovative
treatment options and the development of drugs enabling personalized therapeutic protocols are
necessary. The aim of this review was to give an overview on the most relevant emerging drug
resistance-related biomarkers, therapeutic targets and new agents or novel candidate treatment
strategies, which have been highlighted and suggested for HGOS to improve the success rate of
clinical trials.
Abstract: High-grade osteosarcoma (HGOS), the most common primary malignant tumor of bone,
is a highly aggressive neoplasm with a cure rate of approximately 40–50% in unselected patient
populations. The major clinical problems opposing the cure of HGOS are the presence of inherent
or acquired drug resistance and the development of metastasis. Since the drugs used in first-line
chemotherapy protocols for HGOS and clinical outcome have not significantly evolved in the past
three decades, there is an urgent need for new therapeutic biomarkers and targeted treatment
strategies, which may increase the currently available spectrum of cure modalities. Unresponsive or
chemoresistant (refractory) HGOS patients usually encounter a dismal prognosis, mostly because
therapeutic options and drugs effective for rescue treatments are scarce. Tailored treatments for
different subgroups of HGOS patients stratified according to drug resistance-related biomarkers
thus appear as an option that may improve this situation. This review explores drug resistance-
related biomarkers, therapeutic targets and new candidate treatment strategies, which have emerged
in HGOS. In addition to consolidated biomarkers, specific attention has been paid to the role of
non-coding RNAs, tumor-derived extracellular vesicles, and cancer stem cells as contributors to
drug resistance in HGOS, in order to highlight new candidate markers and therapeutic targets. The
possible use of new non-conventional drugs to overcome the main mechanisms of drug resistance in
HGOS are finally discussed.
Keywords: osteosarcoma; drug resistance; personalized medicine; biomarker
1. Introduction
High-grade osteosarcoma (HGOS) is the most common primary malignant tumor
of bone for which the identification of new treatment strategies is highly warranted to
improve the presently achievable clinical cure rates [1,2].
The most common treatment for primary, conventional HGOS (localized in the ex-
tremities, non-metastatic at clinical onset, age lower than 40 years) consists of pre- and
Cancers 2021, 13, 2878. https://doi.org/10.3390/cancers13122878 https://www.mdpi.com/journal/cancers
Cancers 2021, 13, 2878 2 of 23
post-operative chemotherapy regimens based on different combinations of doxorubicin,
methotrexate, and cisplatin with the possible addition of ifosfamide, etoposide and, more
recently, liposomal muramyl tripeptide phosphatidylethanolamine (L-MTP-PE; MEPACT) [1–5].
Unfortunately, intensified treatments with these drugs or with the addition of adjuvant
agents (i.e., interferons or zoledronic acid), which have been performed in the past decades,
have failed to significantly improve cure rates of conventional HGOS patients [1,6–8].
Other drugs, such as vincristine, 5-fluorouracil, bleomycin, cyclophosphamide,
actinomycin-D, docetaxel, and gemcitabine, among others, proved to be less active and are
presently considered only for second-line and rescue chemotherapy protocols, which are
far from being standardized [1,9].
The major clinical problem that severely limits the success of HGOS treatment is
inherent or acquired drug resistance which, together with development of metastasis,
causes the dismal prognosis of relapsed patients, for whom cure probability does not exceed
20–25% [10–12]. Therefore, the identification, characterization and clinical validation of
drug resistance-related biomarkers is mandatory to indicate new candidate therapeutic
targets and novel agents, which may be considered to improve the successful rate of clinical
trials for HGOS.
This review is focused on the drug resistance-related biomarkers proven to be of
relevant clinical impact or which have recently emerged in HGOS as new candidate
therapeutic targets to indicate novel treatment strategies aimed to overcome drug resistance
and improve patients’ outcome.
The involvement of the microenvironment, signal transduction pathways or cell cycle
and apoptosis disruptions on drug resistance was not considered since it has recently been
reviewed in detail [13,14]
2. Consolidated and Emerging Drug Resistance-Related Biomarkers
2.1. ABC Transporters
Drug resistance remains the most significant obstacle to successful treatment for HGOS,
in which one of the main reasons for clinical drug unresponsiveness is the overexpression
of the membrane drug transporter ATP binding cassette (ABC) subfamily B member 1
(ABCB1), also known as P-glycoprotein. Several studies have investigated the clinical
relevance of ABCB1 expression in HGOS progression, treatment response, or outcome,
and the provided results have sometimes been controversial [15–19]. However, different
meta-analyses demonstrated that increased ABCB1 protein expression at diagnosis can
predict poor survival in HGOS patients [20,21]. Based on this evidence, the overexpression
of ABCB1 at diagnosis has been used to design a treatment protocol conducted by the
Italian Sarcoma Group, of which the results are presently under revision [5].
Although ABCB1 is a robust negative predictive biomarker in HGOS patients, the
analysis of co-expression patterns may lead to the discovery of further biomarkers asso-
ciated with poor chemosensitivity. For instance, HGOS patients with high expression of
both ABCB1 and excision repair cross-complementation group 1 (ERCC1) were shown
to have a worse response to neo-adjuvant chemotherapy compared to patients with high
ABCB1 overexpression only [22]. This finding is consistent with reduced damage elicited by
chemotherapy, due to the simultaneous increased DNA repair and enhanced drug efflux.
Since the role of ABC transporters in HGOS has recently been reviewed [14] it has not
been further overviewed in detail in this manuscript.
2.2. DNA Repair Factors
Three of the most widely used first-line HGOS chemotherapeutic drugs generate either
direct (cisplatin and ifosfamide) or indirect (doxorubicin) DNA damage. This damage is
mended by different repair pathways, which include direct repair (DR), nucleotide excision
repair (NER), base excision repair (BER), mismatch repair (MMR), single strand break
repair (SSBR), double strand break repair (DSBR), nonhomologous end joining (NHEJ) and
homologous recombination repair (HRR) [23].
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The DNA repair pathways that have most often been linked to drug resistance in
HGOS are NER and BER, which may interfere with sensitivity to both first-line and second-
line drugs used in this tumor [1,9,24]. Altered expression of different excision repair
cross-complementation (ERCC) genes, belonging to the NER pathway, have been reported
to be associated with worse prognosis [22] or histological response [25]. Moreover, drugs
targeting NER/BER pathways have recently been indicated to be of possible clinical interest
to overcome cisplatin unresponsiveness in HGOS [26].
Genetic polymorphisms affecting ERCC1 and excision repair cross-complementation
group 2 (ERCC2) genes have been studied and were associated with treatment response
and/or survival of HGOS patients [1,24,27].
The expression of apurinic/apyrimidinic exonuclease 1 (APEX1 or APE1), a gene
belonging to the BER pathway, was reported to be amplified and overexpressed in HGOS
clinical samples [28]. APEX1 increased expression was described to be associated with
a trend toward a reduced chemotherapy response and to significantly correlate with
development of tumor recurrence and metastasis [28]. Thus, if APEX1 expression level
is further confirmed as a prognostic marker for HGOS, it might be considered as a new
potential therapeutic target for this tumor.
Another BER gene that has been explored in HGOS is poly(ADP-ribose) polymerase
1 (PARP1). In a recent study performed in a series of relapsed and unresectable HGOS
patients, high PARP1 expression showed a clear trend towards an association with worse
outcome, but did not reach statistical significance [29]. On the basis of these and other
clinical evidence, which showed encouraging activity of the PARP inhibitor olaparib in
bone and soft-tissue sarcomas [30], targeting PARP appears to be a promising therapeutic
strategy to be further explored. Phase 2 clinical trials with the PARP inhibitor olaparib
used alone (ClinicalTrials.gov Identifier: NCT03233204) or in combination with the ataxia
telangiectasia and rad3 related (ATR) kinase inhibitor ceralasertib in patients with unre-
sponsive, refractory or recurrent HGOS (ClinicalTrials.gov Identifier: NCT04417062) are
presently ongoing. The rationale of the latter combination derives from the fact that ATR is
another essential regulator of the DNA damage response, which increased expression and
activation was shown to correlate with shorter HGOS patient survival and lower extent of
tumor necrosis following neoadjuvant chemotherapy [31].
Recently, it has also been demonstrated that nitric oxide (NO) can sensitize cells to
DNA damaging drugs through the induction, nitrosation and denaturation of several pro-
teins which are involved in DNA repair, indicating new possible strategies for future thera-
peutic intervention, despite limitations must still be resolved for clinical applications [32].
Moreover, NO induces the depletion of GSH that generally inactivates platinum(Pt)-based
drugs, thus contributing to reverse resistance against DNA damaging agents.
2.3. Methotrexate Resistance-Related Factors
Another key agent for HGOS treatment is methotrexate, an antifolate drug, which
binds to the dihydrofolate reductase (DHFR) enzyme, leading to inhibition of DNA syn-
thesis and replication, and ultimately causing apoptosis. Increased levels of DHFR have
been reported to be one of the major mechanisms responsible for methotrexate resistance in
HGOS, along with impaired drug transport due to decreased expression of the membrane-
located solute carrier family 19 (folate transporter) member 1 (SLC19A1; also known as
reduced folate carrier, RFC or reduced folate carrier 1, RFC1) [33]. In order to overcome
these and other common mechanisms of methotrexate resistance, different antifolates have
been studied in several experimental models and a few of them have also been evalu-
ated at clinical level, unfortunately without showing activity superior to that exhibited by
methotrexate [1,33].
Polymorphisms affecting genes involved in methotrexate transport and metabolism
have also been studied and indicated to mediate drug activity and collateral toxicity [27,33],
but further investigations and functional analyses are needed before this body of informa-
tion can effectively be transferred into clinical practice.
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2.4. Extracellular Vesicles
Several studies performed in different cancers have shown the importance of extra-
cellular vesicles (EVs) in intercellular communication and the interchange of bioactive
molecules between tumor and resident cells [34]. These vesicles include exosomes, mi-
crovesicles, oncosomes, and microparticles. Recent research findings have strongly sup-
ported EVs as key players in mediating drug unresponsiveness and in conferring resistance
to drug-sensitive cells in different tumors [34–37], with increasing evidence also emerging
in HGOS.
Different studies have shown that EVs can mediate drug resistance in HGOS through
the transfer of coding and non-coding RNAs.
The spread of doxorubicin resistance between different HGOS cell populations was
shown to occur through transfer of EVs carrying drug efflux pumps [38]. This study showed
that EVs were able to decrease sensitivity to doxorubicin by transferring functional MDR-1
mRNA (encoding for ABCB1) in MG-63, HGOS cells [38]. The demonstration of EVs release
containing MDR-1 mRNA from HGOS doxorubicin-resistant cells suggested that this may
be a mechanism through which resistant tumor cells may spread drug unresponsiveness to
sensitive cells, contributing to tumor chemoresistance [38].
Recently, it has been reported that exosomes can mediate chemoresistance of HGOS
cells by transmitting circular RNAs (circRNAs) [39]. In this study, the expression of
hsa_circ_103801 was found to be upregulated in cisplatin-resistant MG63 cells compared
with their drug-sensitive parental cells. Moreover, in the same study, it was found that
hsa_circ_103801 was highly present in exosomes derived from cisplatin-resistant cells, and
that its spread through these microvescicles was able to decrease the cisplatin sensitivity
of MG63 and U2OS HGOS cells, as well as to inhibit apoptosis and increase expression of
ABCC1 and ABCB1 [39]. These findings may also indicate exosomal hsa_circ_103801 as a
new candidate target to be considered for overcoming HGOS chemoresistance.
In another study [40], dysregulation of miR-25-3p, which inhibits the expression
of the dickkopf WNT signaling pathway inhibitor 3 (DKK3) gene, was detected in human
HGOS tissues and proved to be negatively correlated with clinical outcome. The same
authors demonstrated that, in HGOS experimental models, miR-25-3p upregulation pro-
moted tumor growth, invasion, and drug resistance, and that these same effects were
also detected after DKK3 silencing. Interestingly, miR-25-3p was found to be present in
tumor-derived exosomes, suggesting that it may exert its oncogenic functions through
EVs-mediated dissemination.
Exosome protein cargos were also recently studied by using canine osteosarcoma
experimental models and clinical samples [41]. In this study, the protein content of exo-
somes derived from two canine osteosarcoma, carboplatin-resistant variants (HMPOS-2.5R
and HMPOS-10R) was compared to that of their drug-sensitive parental cell line HMPOS.
Authors demonstrated that exosomes exhibited distinct protein signatures related to drug
resistance and that exosomes from the resistant HMPOS-2.5R variant were able to transfer
drug resistance to drug-sensitive HMPOS cells. When circulating exosomes from dogs
with a favorable disease-free interval were compared with those from dogs with poor
clinical outcome, a proteomic signature discriminating between the two cohorts could be
identified, with several putative biomarkers shared with the aforementioned cell lines.
This study highlighted the potential significance of exosomes in transferring drug resis-
tance in canine osteosarcoma and indicated novel candidate biomarkers, which may be
considered to monitor treatment response through liquid biopsy with the aim to better
personalize chemotherapy.
Liquid biopsy has been explored also in human HGOS as a non-invasive method of
studying circulating elements [42]. Therefore, the isolation of circulating EVs and analysis
of their cargo may become a promising approach to discover and validate new biomarkers
that could be used to improve treatment efficacies.
Further studies are however warranted to define the actual impact of EVs and exo-
somes for preclinical and clinical drug resistance in HGOS. If their involvement in HGOS
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drug resistance will be confirmed, new therapeutic avenues based on the strategy of
mimicking EVs with micelleplexes or lipid-based nanoparticles to deliver drugs or RNA
molecules to overcome or reverse chemoresistance may be proposed to design innovative
clinical trials [43,44]. However, it must be underlined that the clinical use of exosomes still
encounters several limitations [45]. Future research in this field should thus be devoted to
improving their production and storage conditions to prevent loss of function and assure
the long-term safety of exosome-based therapies.
2.5. Non-Coding RNAs
Non-coding RNAs (ncRNAs) include a large number of RNA subclasses, which are
not transcribed into proteins and are mainly involved in the regulation of gene expression.
According to their length, they can be classified as small non-coding RNA (sncRNA),
long non-coding RNA (lncRNA) and circRNA. sncRNAs include the categories of small
interfering RNA (siRNAs), micro RNAs (miRNAs), transfer RNAs and some ribosomal
RNA. In recent years, an increasing number of ncRNAs have been suggested to play a
role in HGOS tumorigenesis, invasion, metastatic progression, apoptosis and also in drug
resistance [27].
The most widely studied ncRNAs are miRNAs and lncRNAs. miRNAs are single-
stranded RNA fragments that repress target messenger RNAs (mRNAs) and play signifi-
cant roles in multiple cellular processes [46]. Recently, several studies have indicated their
involvement also in HGOS drug resistance [27,47,48]. Since this subject has recently been
reviewed extensively [48], we have commented here on only a few reports, which highlight
particular aspects of miRNA involvement in HGOS drug unresponsiveness.
Lin and coworkers [49] observed a correlation between miR-184 and doxorubicin resis-
tance in HGOS cells. In particular, this study showed that in HGOS cells, elevated levels of
miR-184 decreased doxorubicin sensitivity by targeting Bcl-2-like protein 1 (BCL2L1),
an antiapoptotic protein, which promotes cell survival facilitating the acquisition of
drug resistance.
Down-regulation of miR199a has been revealed in cisplatin-resistant HGOS cells and
clinical samples [50]. This study demonstrated that overexpression of miR199a reversed
cisplatin resistance targeting the hypoxia-inducible factor 1-alpha (HIF-1α), a transcription
factor involved in the cellular adaptation to hypoxia [50].
Another study focused on the role of miR29 family for methotrexate resistance in
HGOS [51]. The miR-29 family targets collagen type III Alpha 1 chain (COL3A1) and
induced myeloid leukemia cell differentiation protein (MCL1). miR-29a, miR29b and
miR29c were found to be downregulated in two methotrexate-resistant HGOS cell lines.
In agreement with this observation, this study showed that overexpression of miR29a,
miR29b and miR29c was able to sensitize methotrexate-resistant human HGOS cell lines to
this drug by promoting apoptosis through the regulation of COL3A1 or MCL1.
In general, the so far reported body of evidence has indicated miRNAs as candidate
predictive biomarkers of poor drug response, with the possibility to be taken into consid-
eration also as therapeutic targets to reverse drug resistance, once their role in HGOS is
confirmed and validated.
lncRNAs are RNA molecules more than 200 nucleotides in length, which play regula-
tory roles in different biological processes and diseases by interacting with DNA, RNA and
proteins [52]. Several lncRNAs have been found to be aberrantly expressed in HGOS, show-
ing some correlation with clinical outcome, disease status and drug resistance [27,48,53]. A
list of the lncRNAs with the most relevant impacts on drug resistance, together with their
mechanism of action, is presented in Table 1.
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Table 1. List of non-coding RNAs indicated to be involved in osteosarcoma drug resistance.
Name Expression Mechanism References
LncRNA Targeting miRNAs
LINC00161 Down-regulated Promotes apoptosis by sponging miR-645 andupregulating IFIT2 [54]
SNHG16 Up-regulated Increases cisplatin-resistance upregulating ATG4Bby sponging miR-16 [55]
TTN-AS1 Up-regulated Increases cisplatin-resistance promoting MBTD1expression by targeting miR-134-5p [56]
NCK-AS1 Up-regulated Increases cisplatin-resistance upregulating MRP1 bytargeting miR-137 [57]
ROR Up-regulated Increases cisplatin-resistance upregulating ABCB1by targeting miR-153-3p [58]
SNHG12 Up-regulated Increases doxorubicin resistance promoting theexpression of MCL1 by targeting miR-320a [59]
LUCAT1 Up-regulated Increases methotrexate resistance upregulatingABCB1 by targeting miR-200c [60]
NEAT1 Up-regulated Increases cisplatin resistance sponging miR-34c [61]
SARCC Down-regulated
Increases cisplatin sensitivity promoting miR-43




Increases Doxorubicin sensitivity promoting
apoptosis by binding miR-210 and
inhibiting autophagy
[63]
OIP5-AS1 Up-regulated Increases doxorubicin resistance upregulating PTNby targeting miR-137-3p [64]
MIR17HG Up-regulated Increases cisplatin resistance suppressingmiR-130-3p and upregulating SP1 [65]
NORAD Up-regulated Increases cisplatin resistance targeting miR-410-3p [66]
LncRNA Targeting ABC Transporters
FOXC2-AS1 Up-regulated Increases doxorubicin resistance upregulatingABCB1 by increasing FOXC2 [67]
ODRUL Up-regulated Increases doxorubicin resistance increasingABCB1 expression [68]
FENDRR Down-regulated Increases doxorubicin sensitivity promotingapoptosis and down regulating ABCB1 and ABCC1 [69]
In general, the number of lncRNAs which may be involved in HGOS drug resistance
is continuously increasing [27,48]. Indeed, Zhu and coworkers [70], by studying three sets
of HGOS doxorubicin-resistant MG63/DXR cells in comparison with the parental MG63
cell line, identified 3465 lncRNAs (1761 up- and 1704 down-regulated) that were aberrantly
expressed in resistant cells. On the same experimental models, these authors also found
3278 miRNAs that were either up- (1607) or down-regulated (1671), further supporting the
deep involvement of different categories of ncRNAs in HGOS drug resistance which, once
sufficiently validated, may become new biomarkers to predict patients’ drug responsivity.
An example of the crucial role of lncRNAs in drug resistance is the evidence that
lncRNA FOXC2 antisense RNA 1 (FOXC2-AS1) can enhance the expression of FOXC2,
subsequently increasing the ABCB1 levels and leading to doxorubicin resistance [67].
Another lncRNA involved in doxorubicin resistance in HGOS is the osteosarcoma
doxorubicin resistance-related up-regulated lncRNA (ODRUL), which was found to be the
most up-regulated lncRNA in doxorubicin-resistant HGOS cells [68]. Moreover, this study
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showed that lncRNA ODRUL was increased in HGOS patients with poor chemotherapy
response and lung metastasis, and that its inhibition could decrease OS cell proliferation,
migration, and partly reverse doxorubicin resistance in vitro. Since ABCB1 gene expression
was also decreased after lncRNA ODRUL knockdown, the authors concluded that lncRNA
ODRUL may act as a pro-doxorubicin-resistant molecule through the induction of ABCB1
overexpression in HGOS cells [68].
An interesting mechanism that has recently been described to play a key role in
HGOS drug resistance is the so-called sponging activity of some lncRNAs (Figure 1),
which bind miRNAs suppressing their regulatory functions [71]. For example, Fu and
coworkers [56] found that the lncRNA TTN-AS1 is highly expressed in HGOS, in which
it inhibits apoptosis and induces drug resistance by targeting miR-134-5p promoting
expression of the malignant brain tumor domain 1 (MBTD1), a gene belonging to the
polycomb family, involved in transcription processes. In agreement with this observation,
MBTD1 was found to be correlated with a poor prognosis in HGOS patients [56].
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activity, lncRNAs can regulate mRNA expression by competitively bin i c l entary miRNAs and, consequently,
opposing their interaction with target mRNAs. Figure shows some lncRNAs that are overexpressed in osteosarcoma cells
and negatively modulate the expression of target genes by sponging their regulatory miRNAs.
Some lncRNAs have also been found to modulate the expression of drug efflux
proteins belonging to the ABC transporter family. For ex mple, it was reported that
in HGOS cells, NORAD can induce overexpression of ABCC1 by suppressing miR-137
through a sponging mechanism [66].
In another study, the lncRNA ROR was found to be upregulated in cisplatin-resistant
HGOS tissues and cell lines, in which it increased ABCB1 expression by sponging its
negative regulator miR-153-3p [58].
2.6. Cancer Stem Cells
Tumor drug resistance may also be ascribed to subpopulations of cells with stemness
properties and, consequently, termed cancer stem cells (CSCs). These cells can divide
both into other CSCs, replenishing their own pool, and into cancer cells with different
characteristics, increasing the intratumor heterogeneity [72]. CSCs were first identified in
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bone sarcomas by Gibbs and colleagues (2005) [73], who described their presence in both
HGOS human specimens and cell lines. These cells were able to form spherical colonies
called “sarcospheres” in non-adherent serum-free conditions and displayed markers as-
sociated with mesenchymal stem cells (MSCs) and embryonic cells [73]. However, the
detection of CSCs in HGOS remains elusive, and putative candidates could be identified
among undifferentiated MSCs or more committed osteoprogenitor cells, which underwent
de-differentiation upon loss of p53 and retinoblastoma (Rb) genes [74].
More convincing evidence reported so far on HGOS CSCs indicated that their pheno-
type was characterized by increased expression of stemness-related factors, such as SRY
(sex determining region Y)-box 2 (Sox2) [75], Kruppel-like factor 4 (KLF4) [76], octamer-
binding transcription factor 3/4 (Oct3/4) and homeobox protein Nanog [77]. Among
these, Sox2 was suggested as the most relevant marker of sarcoma CSCs, being crucial in
sarcomagenesis [78].
One of the pivotal features displayed by HGOS CSCs is chemoresistance, which is
frequently associated with increased metastatic ability [75]. This chemoresistant phenotype
may derive from different mechanisms (Figure 2), among which the overexpression of
ABC transporters [79], enhanced DNA repair activities [80], and altered modulation of
apoptosis-related genes [81] can be mentioned. For instance, Roundhill and coworkers [82]
recently indicated that HGOS CSCs exhibit elevated levels of ABCB1 and ATP binding
cassette subfamily G member 1 (ABCG1), which may confer to these cells resistance against
different drugs used for HGOS treatment such as doxorubicin, etoposide, vincristine, and
actinomycin D.
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Figure 2. Involvement of osteosarcoma cancer stem cells in drug resistance. Osteosarcoma cancer stem cells (OS CSCs)
represent a relatively small subpopulation in the tumoral bulk, characterized by high expression of stemness-related
transcription factors (such as Sox2, Oct3/4, Nanog and Klf4). These characteristics promote self-renewal capability and
enhanced multipotency, which enable OS CSCs to persist and to generate neoplastic cells as well, replenishing the tumoral
bulk, i. ., following chemotherapy or surgical interventions. Nonetheless, the m t critical feature of OS CSCs is enhanced
drug resistance towards the ain anti-neoplastic agents involved in high-grade osteosarcoma treatment, as a consequence
of different mechanisms (the most relevant of which are shown in this Figure). Such chemoresistance may be enforced by
aberrant miRNA expression and by alteration of different signaling pathways mainly induced by stimuli of the tumoral
microenvironment.
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Lee and colleagues [83] reported that MDR1 (encoding for ABCB1) and DHFR genes
were upregulated in HGOS stem-like cells, which were respectively resistant to doxorubicin
and methotrexate.
Drug resistance of HGOS CSCs may also be influenced by epigenetic factors, which
can modulate the expression profile of these cells. Di Fiore and colleagues [84] performed a
molecular and genetic characterization of the 3AB-OS CSC line, which was derived from
the MG-63 human HGOS cell line, and identified 189 miRNAs which were differentially
expressed compared to parental cells, of which 37 were expressed only by the 3AB-OS
cells. Among these, miR-29b-1 overexpression was found to be correlated with drug
resistance [85]. Moreover, in another study performed on the same cell line, overexpres-
sion of miRNA let7-d was found to confer resistance towards several drugs [86], further
confirming the role of miRNAs in acquisition of drug resistance by CSCs.
Finally, alterations of several signaling pathways have been implied in the origin and
maintenance of HGOS CSCs subpopulations, despite not being directly associated with
drug resistance. They include mitogen-activated protein kinase (MAPK) [87], Notch [88],
Hedgehog [89], Wnt/β-catenin [90], bone morphogenetic protein 2 (BMP-2) [91], trans-
forming growth factor beta 1 (TGF-β1) [92] and tumor necrosis factor alpha (TNFα) [93].
These factors and pathways are of interest because they may be considered as potential
targets for therapy to prevent or inhibit the CSC phenotype. Indeed, the Wnt pathway was
efficiently targeted by a tankyrase inhibitor in preclinical models of HGOS cancer stem-like
cells [94], whereas acquisition of HGOS CSC phenotype was prevented by inhibition of the
TGFβ pathway via single-walled carbon nanotubes [95].
CSCs may also be key players in microenvironment-related conditions that are im-
portant in determining the expression of several ABC transporters. Hypoxia, for instance,
induces the HIF-1α transcriptional factor that up-regulates ABCB1 [96] and the activity
of Notch homolog 1 (Notch1), which increases ABCC1 [97] thus inducing resistance to
doxorubicin and methotrexate. Since active Notch1 was often found in aggressive and
chemoresistant HGOS rich of CSCs [98], it cannot be excluded that the hypoxic niche selects
CSC-like cells, which are by nature enriched of ABC transporters expression.
Indeed, HGOS cells isolated as side-population of CSC-like elements display high
expression of ABCB1, ATP binding cassette subfamily B member 2 (ABCB2), ABCG2 [78]
and ATP binding cassette subfamily B member 5 (ABCB5) [99–101]. Notably, doxorubicin
and, to a lesser extent, cisplatin and methotrexate, increases typical stemness markers
including aldehyde dehydrogenase 1 family member A1 (ALDH1A1), Sox2, Oct4 and the
Wnt/β-catenin pathway, which in turn up-regulates ABCB1 and ABCG2 [102]. Therein,
chemotherapy may create a vicious circle that progressively selects CSCs with a more ag-
gressive and chemoresistant phenotypes. This is consistent with other findings demonstrat-
ing that the selection in doxorubicin containing culture medium increases the proportion
of HGOS cells with self-renewal capacity and high levels of ABCB1 [82], likely mimicking
a process occurring during chemotherapeutic treatment in unresponsive patients.
3. Emerging Candidate Therapeutic Targets and Treatment Modalities
3.1. Chemorevertants and Emerging Modalities to Overcome Drug Resistance in HGOS
The most frequently studied approaches to circumvent ABC-mediated drug resistance
have been based on the co-administration of chemotherapeutic drugs, which are substrates
of these transporters, with compounds inhibiting ABC activity. During the last 30–40
years, different generations of ABC inhibitors have been developed, in order to obtain
agents with higher efficacy and specificity together with fewer adverse toxicities and
lack of antagonistic pharmacokinetic interactions with conventional chemotherapeutic
drugs [97]. Unfortunately, when translated to clinical practice, these agents have shown
limited therapeutic potential, mostly because of the severe toxic side effects observed at the
concentrations required to significantly inhibit ABC transporter activity [103,104].
The most commonly studied ABC transporter is ABCB1, for which hundreds of
biologically active compounds have been reported to act as its substrates and/or inhibitors.
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By taking into consideration the aforementioned clinical relevance of this transporter for
HGOS, several strategies for reversing and preventing drug resistance by targeting ABCB1
have been studied in HGOS experimental models.
Recently, we provided evidence that the newly generated ABCB1/ABCC1 inhibitor
CBT-1® (Tetrandrine, NSC-77037) may be considered as a potential adjuvant to standard
chemotherapy in ABCB1-overexpressing HGOS patients (Figure 3) [105]. On the basis of
these and other preclinical findings, an ongoing, recruiting phase I trial (ClinicalTrials.gov
identifier: NCT03002805) is evaluating the clinical efficacy of the combination of CBT-1®
and doxorubicin for the treatment of metastatic, unresectable sarcoma (including HGOS)
patients, who have progressed after treatment with doxorubicin.
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Natural compounds or plant extracts have also been reported to act as potent ABCB1
inhibitors, exhibiting low collateral toxicity and good oral bioavailability [106]. Among
these, curcumin was included in a Phase I/II clinical trial for relapsed or metastatic high-
grade OS patients (ClinicalTrials.gov identifier: NCT00689195), for which however no
results have been posted yet, despite its estimated completion date being set for June 2013.
The rational of this approach was based on the fact that curcumin, a phenolic compound
used in traditional Indian and Asian medicine, proved to inhibit several ABC transporters,
including ABCB1 [107]. We also demonstrated that curcumin was able to decrease the
ABCB1 transport activity in doxorubicin-resistant human HGOS cell lines, even if with
a remarkably lower efficiency compared to other ABCB1 inhibitors [105]. Unfortunately,
due to the lack of clinical information, it is not possible to indicate whether curcumin or
curcuminoids might be of interest for HGOS treatment.
An alternative way to interfere with ABCB1 activity has emerged from studies on
tyrosine kinase inhibitors (TKIs), which can be at the same time substrates but also down-
regulators of ABC transporters activity by interfering with ATP-binding, therefore acting
as chemoresistance revertants [108–110].
We have provided evidence that TKIs can be both ABCB1 substrates but also act as
down-regulators of ABCB1-mediated resistance in HGOS experimental models. Indeed,
we showed that the Aurora kinase inhibitor VX-680 (MK-0457, Tozasertib) (Figure 3) was
less active in doxorubicin-resistant, ABCB1-overexpressing human HGOS cell lines but
its combined administration together with doxorubicin proved to partially overcome
resistance, most probably because the simultaneous presence of two ABCB1 substrates
prevented this transporter from sufficiently extruding both drugs from the intracellular
compartment [111]. Therefore, despite the fact that overexpression of ABCB1 and other
ABC transporters can confer resistance to TKIs, thus limiting their use as single agents for
cancer treatment [108,110], the association of these agents with conventional drugs, such
as doxorubicin, may open new perspectives to overcome drug resistance in chemotherapy
unresponsive patients.
Overcoming drug resistance may also take advantage of nanomedicine and studies
on polymeric micelles, which may be considered for the targeted transportation of poorly
water-soluble drugs or agents. The possibility of using polymeric micelles encapsulating
miRNAs to actively target HGOS cells and overcome multidrug resistance has recently
been reviewed [112]. Once candidate miRNAs and ncRNAs that have been indicated to be
associated with drug resistance in HGOS will be sufficiently validated, this approach may
be proposed as a novel therapeutic strategy.
If the role of EVs and exosomes in transferring drug resistance as described above
is confirmed and validated, two possible additional treatment strategies to overcome
resistance may be considered. The first one might be based on the inhibition of EV secretion
by HGOS cells, but this approach is presently limited by the lack of agents that can
specifically target EV secretion by cancer cells [34]. The second possibility might be the
specific removal of tumor-derived EVs involved in the transfer of drug resistance, an
approach that is presently under preclinical evaluation and has the advantage of not
interfering with the normal secretion of “beneficial” EVs [34].
Additional emerging therapeutic strategies have been recently reviewed and are
therefore not discussed in detail in this review [1,113].
3.2. Modified Conventional Drugs to Overcome Resistance in HGOS
Modification of already used chemotherapeutic drugs to produce synthetic agents
exploiting specific metabolic vulnerabilities of resistant HGOS cells can be considered a
promising chemosensitizing strategy. For instance, we found that U-2OS cell sublines
with progressive increase in resistance to doxorubicin, also have a progressively increased
mitochondrial mass and energetic metabolism based on tricarboxylic acid (TCA) cycle, fatty
acid β-oxidation (FAO) and electron transport chain (ETC) [114]. A doxorubicin conjugated
with a tripeptide vectorizing the drug toward mitochondria (Figure 3) dramatically reduced
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the number of mitochondria and induced damages in the mitochondrial DNA, impairing
the transcription of several genes encoding energetic metabolism [115]. Such mitochondrial
catastrophe dramatically reduces the oxidative-phosphorylation (OXPHOS)-linked produc-
tion of ATP, increases the amount of reactive oxygen species (ROS) of mitochondrial origin
and induces mitochondrial depolarization, triggering apoptosis. In our experimental mod-
els, these events were more pronounced in HGOS resistant cells, likely because they rely
more on aerobic mitochondrial metabolism than sensitive cells, and were translated into
the rescue of in vivo doxorubicin efficacy [114]. Since the heart is the main tissue damaged
by doxorubicin and strongly relies on aerobic mitochondrial metabolism, the risk of such
an extremely effective drug is to worsen the cardiac damage elicited by doxorubicin. Curi-
ously, although the mitochondrial targeting doxorubicin reduced mitochondrial mass and
energy metabolism in heart, normal cardiomyocytes showed a tremendous ability to com-
pensate by promptly increasing the mitochondrial mass, differing from cancer cells [116].
Indeed, mice treated with this synthetic doxorubicin presented lower levels of creatine
phosphokinase-MB (CPK-MB) than animals treated with parental doxorubicin [116]. Over-
all, these data suggest that mitochondrial targeting doxorubicin could be a promising
compound to be tested in phase I clinical trials.
A second synthetic doxorubicin that may act with a similar mechanism is a nitrooxy-
conjugated doxorubicin (Figure 3), a prodrug that, thanks to its high lipophilicity, is
accumulated within mitochondria, where it is broken into doxorubicin and nitric ox-
ide (NO) [117]. In mitochondria, NO inhibits aconitase, a critical enzyme of TCA cycle,
and the Fe-S-cluster containing proteins of the ETC, triggering a strong mitochondrial-
dependent apoptosis [117]. Although not yet tested in HGOS, the liposomal formulation
of this nitrooxy-doxorubicin demonstrated a good efficacy in doxorubicin-resistant triple
negative breast cancer, coupled with a lower cardiotoxicity compared to native doxoru-
bicin [118]. Hence, nitrooxy-doxorubicin is a new agent to be studied in HGOS in order
to verify whether it might represent a new option for the treatment of HGOS refractory
to doxorubicin. This approach might also have an additional advantage since it has been
demonstrated that NO can deplete GSH, thus reducing cisplatin inactivation and enhancing
its activity [119].
Another key difference between doxorubicin-sensitive and -resistant cells is the dif-
ferential response to endoplasmic reticulum (ER) stress, which is impaired in HGOS and
other cancer cells with acquired resistance to doxorubicin [120,121]. When proteins are
folded within ER lumen, they are physiologically subjected to a quality control, carried out
by the ER-associated protein degradation/ER-quality control (ERAD/ERQC) machinery
associated to ER membrane. If the protein is correctly folded, it is delivered to its final desti-
nation; on the contrary, if it has misfolded/unfolded portions it is extracted, ubiquitinated
and primed for proteasomal degradation [122]. Interestingly, HGOS cells with increased
resistance to doxorubicin up-regulate several proteins of the ERAD/ERQC complex [123],
likely because the constant pressure exerted by the drug in the culture medium stimulates
cells to deal with damaged proteins, which must be removed to prevent the activation of
ER stress-dependent apoptotic pathways. ERAD/ERQC complex, however, works at its
maximal efficacy in resistant HGOS cells and can be easily overwhelmed by perturbing
agents. To this aim, we designed a synthetic doxorubicin releasing H2S (Figure 3), devoid
of any oxidative damaging effects on cardiomyocytes but still able to kill doxorubicin
resistant osteosarcoma cells [124]. The drug, indeed, is accumulated within the ER where
it sulfhydrates several nascent proteins, accumulating the burden of unfolded proteins
and activating the CCAAT/enhancer binding protein-β liver inhibitory protein (C/EBP-β
LIP)/C/EBP-β homologous protein (CHOP)/p53 upregulated modulator of apoptosis
(PUMA)/caspases 12-7-3 pro-apoptotic axis [123]. Similarly to mitochondrial targeting
doxorubicin, the maximal efficiency of H2S-releasing doxorubicin is achieved in resistant
cells, because their ERAD/ERQC system is already saturated under basal conditions and
collapses upon any stimulus, further increasing the burden of misfolded proteins. Notably,
ABCB1 is also folded within the ER and is sulfhydrated by H2S-releasing doxorubicin: this
Cancers 2021, 13, 2878 13 of 23
process alters the stable conformation of ABCB1 [125], determining instead a prominent
ubiquitination of the protein [123]. This provides an additional mechanism explaining the
efficacy of H2S-releasing doxorubicin in murine doxorubicin resistant HGOS models [126],
with perspective of a possible clinical translation.
Platinum-modified compounds have also been studied and some preclinical find-
ings have been reported also for HGOS cells. For example, diaminedichloro-platinum (II)
complex and camptothecin dual compounds proved to overcome cisplatin resistance in
the U2OS/Pt HGOS cell line [127]. Other promising compounds, which have recently
shown interesting preclinical efficacy in HGOS experimental models, include bifunc-
tional platinum(II) complexes with bisphosphonates (showing high affinity for hydroxyap-
atite) [128,129] and platinum complexes containing 8-hydroxyquinoline ligands [130].
Recently, photodynamic therapy has become a new approach to achieve a spatial-
temporal control of tumor killing. In the case of HGOS, the first in vitro assays based on
the combination of cisplatin and low-level laser, which enormously amplifies the ROS
generated by chemotherapy, have been successful in reducing tumor cell viability [131].
Thanks to the high degree of control in terms of killing area, amount and temporal release
of ROS, this photochemotherapeutic approach can be a new promising option to pre-
cisely reduce the tumor mass during surgery or eradicate accessible metastasis refractory
to chemotherapy.
An alternative approach considered the use of MSCs loaded with photosensitizer-
coated fluorescent nanoparticles and the photosensitizer meso-tetrakis (4-sulfonataphenyl)
porphyrin, which were co-cultured with a human HGOS cell line [132]. After irradiation
with light, the release of reactive oxygen species (ROS) was able to trigger cell death of
HGOS cells, proving the efficacy of this approach.
The preclinical research on modified conventional new drugs or physical agents may
set the basis to improve the clinical treatment of HGOS in the near future.
3.3. Nanocarriers and Nanoparticles
Delivery of chemotherapeutic agents by functionalized nanocarriers has been indi-
cated as an effective strategy to protect drugs from rapid clearance, prolong their circulating
time, and increasing their concentration at tumor sites, thus enhancing therapeutic efficacy
and reducing side effects [133].
In recent years a lot of work has been done to formulate and test nanoparticles carrying
conventional drugs used in the chemotherapeutic treatment of HGOS.
Proteins or molecules that are overexpressed on HGOS cells’ surface have been con-
sidered as ligands to interact with nanoparticles and to promote their internalization into
cancer cells, with a consequent anticancer effect [134].
Following the first clinical trial using Caelyx/Doxil, which lead to only modest out-
come improvements of HGOS patients [135], new liposomal formulations have been
prepared to increase the efficacy of liposomal doxorubicin.
The thermo- and pH-sensitive controlled release of doxorubicin from liposomal for-
mulations [136] or the active targeting of surface antigens, as anti-activated leukocyte
adhesion molecule (ALCAM)/CD166) [137] or anti-ephrin alpha 2 (EPHA2) receptor [138],
have improved the efficacy of liposomal doxorubicin compared to untargeted liposomes or
free drug.
Recently, the hyaluronic acid (HA) receptor CD44 has been found to be overexpressed
in HGOS cells and indicated as a new attractive candidate target. Our group has recently
validated the safety and efficacy of HA-liposomal doxorubicin and H2S-releasing doxoru-
bicin against murine drug resistant HGOS [126]: both formulations have shown higher
efficacy than Caelyx. Part of this effect could be due to the decreased expression of ABCB1
induced by HA [139] or by the ubiquitination of this transporter in case of H2S-releasing
doxorubicin [126]. Moreover, the CD44-triggered endocytosis increases the intracellular
delivery of doxorubicin in HA-conjugated liposomes [126].
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To further improve the efficacy of doxorubicin against drug resistant HGOS, codelivery
strategies of doxorubicin plus a sensitizing agent were further developed. For instance, the
EPHA2-receptor targeting liposomal doxorubicin was co-loaded with a siRNA specific for
the JNK-interacting protein 1 (JIP1) [140], a protein involved in doxorubicin resistance [141].
In these dual target liposomes, the siRNA did not interfere with the release of doxoru-
bicin but, at the same time, targeting the EPHA2-receptor increased drug delivery and
cytotoxicity in HGOS cells [140].
Recently, melatonin has been shown to exert a pro-apoptotic effect against HGOS,
likely by down-regulating the X-linked inhibitor of apoptosis (XIAP), survivin and human
telomerase catalytic subunit (hTERT) [142]. The codelivery of doxorubicin and melatonin,
achieved through graphene dendrimers-Fe3O4 nanocarriers, proved to enhance the apop-
tosis elicited by doxorubicin in HGOS cells and human bone-marrow-mesenchymal stem
cells [142].
The use of molecules with high affinity for bone is another strategy that has been
explored to deliver drugs into HGOS. Following this rationale, micelles made of hydrophilic
D-aspartic acid octapeptide and 11-aminoundecanoic acid have shown a prompt absorption
on hydroxyapatite and a good pH-dependent delivery of doxorubicin in Saos-2 cells [143].
Similarly, a hydroxyapatite-doxorubicin conjugate has recently been produced and coated
with the poly(lactide-co-glycolide) (PLGA) polymer: this conjugate is effective in vitro [144],
but its pharmacokinetic and pharmacodynamic profile has not been explored in vivo.
CaCO3-methoxy poly(ethylene glycol)-block-poly(L-glutamic acid) nanoparticles
loaded with doxorubicin exploit the high affinity of the nanocarrier for mineralized tis-
sues, and display higher delivery of doxorubicin, higher anti-tumor efficacy and lower
side-effects than doxorubicin in mice HGOS [145].
Finally, taking advantage of the high bone tropism of aminobisphosphonate, doxoru-
bicin loaded within poly-electrolyte, poly(acrylic acid) functionalized alendronate [146], or
carried by alendronate/low molecular weight heparin-decorated liposomes [147], have
been successfully tested against HGOS xenografts, revealing higher efficacy than the
free drug.
With a combination of multiple technological strategies, liposomal doxorubicin dec-
orated with HA and alendronate has been co-administered with the tumor penetrating
peptide RGD in mice bearing orthotopic HGOS: the sum of high bone tropism induced
by alendronate, increased EPR mediated by RGD, and CD44-triggered endocytosis of
doxorubicin enormously enhanced the effects of the drug in these preclinical models [148].
The liposomal encapsulation of other drugs used as front-line treatment, such as
cisplatin and methotrexate, is more difficult, because the physico-chemical structure of these
chemotherapeutics impairs significant encapsulation of the compounds in the liposomal
bilayer or in the aqueous core. Indeed, the validation of liposomal nedaplatin is very recent
and has shown a discrete efficacy in vitro against U-2OS cells [149].
Nanocarriers other than liposomes, adopting the same strategies used for the active
targeting of doxorubicin, have been successfully developed for these two drugs, such as
cisplatin-loaded calcium phosphate nanocomposites [150], cisplatin-loaded graphene oxide-
hydroxyapatite nanoparticles coated with chitosan [151], cisplatin-bisphosphonate conju-
gates [129], and meso-porous zinc-substituted hydroxyapatite decorated with methotrex-
ate [152]. The cisplatin-bisphosphonate conjugates appeared to be the most promising
agents, since they showed increased anti-tumor efficacy and reduced systemic toxicity in
animal models [129].
One major limitation of most studies performed on nanocarriers is that they have
shown to increase the effects of chemotherapeutic drugs against commercially available cell
lines with low expression of ABC transporters. Only a few studies have tested nanocarriers
against drug-resistant cells, e.g., in cells overexpressing ABCB1. The investigations on
drug-resistant HGOS xenografts will be a critical issue in validating the large series of
formulated nanocarriers to define whether they can be proposed as valid tools to reverse
resistance to conventional chemotherapy.
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Since the standard treatment regimen is based on polychemotherapy, a second crit-
ical issue is to determine if nanoparticle-loaded drugs impact on the efficacy of the co-
administered chemotherapeutics. Only one study demonstrates that the combination of
cisplatin-loaded nanoparticles and doxorubicin has synergistic effects in vitro [153]. The
presence of unexpected drug–drug interactions or undesired in vivo side effects has not
been investigated yet, and is a crucial point in determining the feasibility of nanocarrier-
based strategies in patients.
A second study, using hydrogel formulations co-loaded with doxorubicin, cisplatin
and methotrexate, showed that the hydrogel effectively reduces cell proliferation and
tumor growth of MG-63 and Saos-2 HGOS xenografts, achieving the complete release of
the drugs from hydrogel 11 days after the administration and a good control of tumor
growth until day 16, without signs of organ toxicity [154]. The main limitation of this
fascinating approach is the need for using an intratumor injection of the hydrogel to reach
a high concentration of the chemotherapeutic drug. The efficacy and toxicity after systemic
administration of the hydrogel-based system have not been documented.
Overall, although nanotechnology may offer a variety of advantages compared to
conventional chemotherapy, the feasibility, safety and efficacy of most nanocarrier-based
approaches must be robustly validated in different preclinical models of HGOS before
proceeding to the first clinical trials.
4. Conclusions
Drug resistance is a multifactorial phenomenon in HGOS, as well as in several other
human cancers, and validation of newly indicated chemoresistance-related factors, which
may also act as novel therapeutic targets, is a major challenge to improve effectiveness of
chemotherapy together with a personalization of treatment regimens.
Different approaches, such as pharmacogenomics, genomics, epigenetics, transcrip-
tomics, or proteomics may be combined to define genetic differences which define individ-
ual drug metabolism and responsiveness, leading to the final treatment response of each
individual patient.
The recent development of advanced genomic and proteomic technologies has signifi-
cantly improved drug targets and biomarkers discovery, providing information underlying
the heterogeneous response to anticancer drugs of each individual patient, which is manda-
tory for planning personalized treatments. However, it must be considered that these new
powerful sequencing technologies also have some challenges, mainly due to the existence
of intron–exon, repetitive sequences, and pseudogenes that may reduce clinical annota-
tion. Moreover, non-coding RNAs, which are increasingly emerging as drug resistance
determinants, may not be efficiently detected by all technologies.
Proteomics studies will also be crucial in validating any drug resistance-related gene
expression alteration, in order to indicate biomarkers which may be considered as new
therapeutic targets.
The hoped transfer of novel drug resistance-related biomarkers identified through this
integrated approach into clinical practice should greatly benefit future drug development
for tailored therapies aimed to overcome HGOS drug resistance.
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Abbreviations
ABC ATP-binding cassette
ABCB1 ATP binding cassette subfamily B member 1
ABCB2 ATP binding cassette subfamily B member 2
ABCB5 ATP binding cassette subfamily B member 5
ABCC1 ATP binding cassette subfamily C member 1
ABCC3 ATP binding cassette subfamily C member 3
ABCC4 ATP binding cassette subfamily C member 4
ABCC5 ATP binding cassette subfamily C member 5
ABCG1 ATP binding cassette subfamily G member 1
ABCG2 ATP binding cassette subfamily G member 2
ALCAM anti-activated leukocyte adhesion molecule
ALDH1A1 aldehyde dehydrogenase 1 family member A1
APEX1 or APE1 apurinic/apyrimidinic exonuclease 1
ATR ataxia telangiectasia and rad3 related
BCL2L1 Bcl-2-like protein 1
BER base excision repair
BMP-2 bone morphogenetic protein 2
C/EBP-β LIP CCAAT/enhancer binding protein- β liver inhibitory protein
CHOP C/EBP-β homologous protein
circRNA circular RNA
COL3A1 collagen type III Alpha 1 chain
CPK-MB creatine phosphokinase-MB
CSCs cancer stem cells
DHFR dihydrofolate reductase
DKK3 dickkopf WNT signaling pathway inhibitor 3
DR direct repair
DSBR double strand break repair
EPHA2 ephrin alpha 2
EPR enhanced permeability and retention
ER endoplasmic reticulum
ERAD/ERQC ER-associated protein degradation/ER-quality control
ERCC excision repair cross-complementation
ERCC1 excision repair cross-complementation group 1
ERCC2 excision repair cross-complementation group 2
ETC electron transport chain
EVs extracellular vesicles
FAO fatty acid β-oxidation
FOXC2-AS1 FOXC2 antisense RNA 1
GSH glutathione
GST glutathione-S transferase
GSTP1 glutathione S-transferase P1
HA hyaluronic acid
HGOS high-grade osteosarcoma
HRR homologous recombination repair
hTERT human telomerase catalytic subunit
JIP1 JNK-interacting protein 1
KLF4 Kruppel-like factor 4
L-MTP-PE liposomal muramyl tripeptide phosphatidylethanolamine
lncRNAs long non-coding RNAs
MAPK mitogen-activated protein kinase
MBTD1 malignant brain tumor domain 1
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MCL1 myeloid leukemia cell differentiation protein
miRNAs micro RNAs
MMR mismatch repair
MSCs mesenchymal stem cells
ncRNAs non-coding RNAs
NER nucleotide excision repair
NHEJ non homologous end joining
NO nitric oxide
Notch1 Notch homolog 1
Oct3/4 octamer-binding transcription factor 3/4
ODRUL osteosarcoma doxorubicin-resistance related up-regulated lncRNA
OXPHOS oxidative-phosphorylation
PARP1 poly(ADP-ribose) polymerase 1
PLGA poly(lactide-co-glycolide)
PTN pleiotrophin
PUMA p53 upregulated modulator of apoptosis
Rb retinoblastoma gene
ROS reactive oxygen species
siRNAs small interfering RNA
SLC19A1 membrane-located solute carrier family 19 (folate transporter) member 1
sncRNAs small non-coding RNAs
SNP single nucleotide polymorphism
Sox2 SRY (sex determining region Y)-box 2
SSBR single strand break repair
TCA tricarboxylic acid
TGF-β1 transforming growth factor beta 1
TKIs tyrosine kinase inhibitors
TNFα tumor necrosis factor alpha
XIAP X-linked inhibitor of apoptosis
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